Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sarepta’s Exondys Successor Bounces Back From Clinical Hold But All Eyes On Gene Therapy

Executive Summary

The firm’s exon-skipping Duchenne muscular dystrophy asset will resume clinical study in the US following the lifting of a clinical hold but observers seem more invested in the fate of its gene therapy candidate for the condition.

You may also be interested in...



Finance Watch: Third Harmonic Launches The Largest IPO In Months

Biopharma stock prices overall are trending down again, but standout firms are raising cash, including the first company to price an IPO over $100m since May, Third Harmonic. Also, Sarepta and Alnylam launched large note offerings, totaling $1bn and $900m, respectively.

Duchenne Breakthrough Hopes Rise With More Data From Sarepta Gene Therapy

More data from Sarepta’s mid-stage studies help bolster confidence in the gene therapy but will the US FDA call in the drug for an early appraisal or await Phase III data next year?

Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections

Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel